61 related articles for article (PubMed ID: 35886997)
1. Evaluations of Anticancer Effects of Combinations of Cisplatin and Tirucallane-Type Triterpenes Isolated from Amphipterygium adstringens (Schltdl).
Díaz-Sánchez L; Zentella-Dehesa A; Castro-Torres VA; Silva-Jiménez N; Jacobo-Herrera NJ; Martínez-Vázquez M
Chem Biodivers; 2023 Oct; 20(10):e202300893. PubMed ID: 37695827
[TBL] [Abstract][Full Text] [Related]
2. Iodinated 4,4'-Bipyridines with Antiproliferative Activity Against Melanoma Cell Lines.
Peluso P; Mamane V; Spissu Y; Casu G; Dessì A; Dallocchio R; Sechi B; Palmieri G; Rozzo C
ChemMedChem; 2024 Mar; ():e202300662. PubMed ID: 38489502
[TBL] [Abstract][Full Text] [Related]
3. Investigation of the Long-Term Effects of Amantadine Use in Parkinson's Disease.
Park S; Shin JH; Jeon SH; Lee CY; Kim HJ; Jeon B
J Mov Disord; 2023 May; 16(2):224-226. PubMed ID: 37258283
[No Abstract] [Full Text] [Related]
4. Melanin-The Éminence Grise of Melanoma and Parkinson's Disease Development.
Krasowska D; Małek A; Kurzepa J; Kapka-Skrzypczak L; Krasowska D; Kurzepa J
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067245
[TBL] [Abstract][Full Text] [Related]
5. Daphnetin, a Coumarin with Anticancer Potential against Human Melanoma: In Vitro Study of Its Effective Combination with Selected Cytostatic Drugs.
Wróblewska-Łuczka P; Góralczyk A; Łuszczki JJ
Cells; 2023 Jun; 12(12):. PubMed ID: 37371063
[TBL] [Abstract][Full Text] [Related]
6. Fraxetin Interacts Additively with Cisplatin and Mitoxantrone, Antagonistically with Docetaxel in Various Human Melanoma Cell Lines-An Isobolographic Analysis.
Wróblewska-Łuczka P; Grabarska A; Góralczyk A; Marzęda P; Łuszczki JJ
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613654
[TBL] [Abstract][Full Text] [Related]
7. Additive Interactions between Betulinic Acid and Two Taxanes in In Vitro Tests against Four Human Malignant Melanoma Cell Lines.
Wróblewska-Łuczka P; Cabaj J; Bąk W; Bargieł J; Grabarska A; Góralczyk A; Łuszczki JJ
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077036
[TBL] [Abstract][Full Text] [Related]
8. Synergy, Additivity, and Antagonism between Cisplatin and Selected Coumarins in Human Melanoma Cells.
Wróblewska-Łuczka P; Grabarska A; Florek-Łuszczki M; Plewa Z; Łuszczki JJ
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33430369
[TBL] [Abstract][Full Text] [Related]
9. Synergy, Additivity and Antagonism between Esculetin and Six Commonly Used Chemotherapeutics in Various Malignant Melanoma Cell Lines-An Isobolographic Analysis.
Wróblewska-Łuczka P; Góralczyk A; Łuszczki JJ
Molecules; 2023 May; 28(9):. PubMed ID: 37175299
[TBL] [Abstract][Full Text] [Related]
10. Cannabidiol Interacts Antagonistically with Cisplatin and Additively with Mitoxantrone in Various Melanoma Cell Lines-An Isobolographic Analysis.
Marzęda P; Wróblewska-Łuczka P; Drozd M; Florek-Łuszczki M; Załuska-Ogryzek K; Łuszczki JJ
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743195
[TBL] [Abstract][Full Text] [Related]
11. AM1172 (a hydrolysis-resistant endocannabinoid analog that inhibits anandamide cellular uptake) reduces the viability of the various melanoma cells, but it exerts significant cytotoxic effects on healthy cells: an in vitro study based on isobolographic analysis.
Marzęda P; Wróblewska-Łuczka P; Florek-Łuszczki M; Góralczyk A; Łuszczki JJ
Pharmacol Rep; 2024 Feb; 76(1):154-170. PubMed ID: 38019413
[TBL] [Abstract][Full Text] [Related]
12. Anticancer Activity of Amantadine and Evaluation of Its Interactions with Selected Cytostatics in Relation to Human Melanoma Cells.
Krasowska D; Gerkowicz A; Wróblewska-Łuczka P; Grabarska A; Załuska-Ogryzek K; Krasowska D; Łuszczki JJ
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886997
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the Anticancer Effects of Arvanil and Olvanil When Combined with Cisplatin and Mitoxantrone in Various Melanoma Cell Lines-An Isobolographic Analysis.
Marzęda P; Wróblewska-Łuczka P; Florek-Łuszczki M; Drozd M; Góralczyk A; Łuszczki JJ
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430670
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
